For **Consent** Amendment 4 to: RTOG 1106/ACRIN 6697, Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCI/Local Protocol #: RTOG-1106/RTOG 1106/ACRIN 6697

NCI Protocol Version Date: 2/25/14

<table>
<thead>
<tr>
<th>1st page</th>
<th>The version date was changed for this amendment.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Note:</strong> The changes described below were made in the sample consent that includes the treatment and imaging components AND in the sample consent that includes only the treatment component.</td>
<td></td>
</tr>
</tbody>
</table>

**What will happen if I take part in this research study?**

- Under “First part of treatment: Radiation and Chemotherapy”, the timeframe of treatment for groups 1 and 2 was amended from “6 weeks” to “6-7 weeks” to be consistent with changes made in Section 7.1 of the protocol.
- “During-radiation FDG-PET/CT scan” was amended to indicate that both groups have the imaging at the same time point, “between weeks 3 and 4 of radiation therapy”, to be consistent with the protocol.

**Study Plan**

In the 3rd row, the timeframe of treatment for groups 1 and 2 was amended from “6 weeks” to “6-7 weeks” to be consistent with changes made in Section 7.1 of the protocol.

**Before you begin the study**

The 4th and 6th bulleted items were revised to be consistent with changes made in the protocol.